Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

Abstract Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. The drug targets the JAK/STAT signalling pathway, which is critical in regulating the gliogen...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Han-Chung Lee, Hamizun Hamzah, Melody Pui-Yee Leong, Hadri Md Yusof, Omar Habib, Shahidee Zainal Abidin, Eryse Amira Seth, Siong-Meng Lim, Sharmili Vidyadaran, Mohamad Aris Mohd Moklas, Maizaton Atmadini Abdullah, Norshariza Nordin, Zurina Hassan, Pike-See Cheah, King-Hwa Ling
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/b2cbcfa33d8b42fb93d9fbc95b27e345
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/b2cbcfa33d8b42fb93d9fbc95b27e345

Ejemplares similares